1 – 22 of 22
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
How to manage patients with germline DDX41 variants : Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
(
- Contribution to journal › Article
-
Mark
TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition
(
- Contribution to journal › Article
- 2023
-
Mark
IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate
ETV6::RUNX1-positive leukemia cells in preclinical models.
(
- Contribution to journal › Article
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
- 2020
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
- 2019
-
Mark
FLT3
N676K
drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis
(
- Contribution to journal › Letter
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
- 2017
-
Mark
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells
(
- Contribution to journal › Article
-
Mark
Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib
(
- Contribution to journal › Article
- 2016
-
Mark
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
(
- Contribution to journal › Article
- 2015
-
Mark
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
(
- Contribution to journal › Article
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
- 2014
-
Mark
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
(
- Contribution to journal › Article
-
Mark
RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
(
- Contribution to journal › Letter
- 2013
-
Mark
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.
(
- Contribution to journal › Article
-
Mark
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
(
- Contribution to journal › Article
- 2010
-
Mark
Molecular and functional studies of ABL1 and FGFR1 fusion oncogenes in myeloproliferative neoplasms
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(
- Contribution to journal › Article
-
Mark
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
(
- Contribution to journal › Article
- 2009
-
Mark
Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage
(
- Contribution to journal › Article
- 2007
-
Mark
Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome.
(
- Contribution to journal › Article
- 2003
-
Mark
HAMLET kills tumor cells by an apoptosis-like mechanism--cellular, molecular, and therapeutic aspects.
(
- Contribution to journal › Scientific review